Stock PLSE PULSE BIOSCIENCES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Press Releases Pulse Biosciences, Inc.

Equities

PLSE

US74587B1017

Real-time Estimate Cboe BZX
Other stock markets
 03:20:16 2024-07-11 pm EDT 		5-day change 1st Jan Change
15.8 USD +6.36% Intraday chart for Pulse Biosciences, Inc. +33.15% +31.09%
Jul. 08 Sector Update: Health Care Stocks Softer Late Afternoon MT
Jul. 08 Sector Update: Health Care Stocks Mixed in Afternoon Trading MT

Press Releases

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
PULSE BIOSCIENCES, INC. ANNOUNCES RECEIPT OF FDA BREAKTHROUGH DEVICE DESIGNATION FOR CELLFX NSPFA CARDIAC SURGERY SYSTEM FOR THE TREATMENT OF ATRIAL FIBRILLATION
AQ
Pulse Biosciences, Inc. Announces Receipt of FDA Breakthrough Device Designation for CellFX® nsPFA Cardiac Surgery System for the Treatment of Atrial Fibrillation
BU
Pulse Biosciences, Inc. Announces the Closing of its Rights Offering
BU
Pulse Biosciences, Inc. Announces Preliminary Results for its Rights Offering
BU
PULSE BIOSCIENCES, INC. ANNOUNCES COMMENCEMENT OF RIGHTS OFFERING
AQ
Pulse Biosciences Announces Updated Timing of Rights Offering for Up to $60,000,000
BU
PULSE BIOSCIENCES CELLFX NANOSECOND PULSED FIELD ABLATION TECHNOLOGY TO BE FEATURED IN SEVERAL PRESENTATIONS AT THE HEART RHYTHM SOCIETY 2024 ANNUAL MEETING
AQ
Pulse Biosciences’ CellFX Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm Society 2024 Annual Meeting
BU
Pulse Biosciences Enhances Executive Leadership Team
BU
Pulse Biosciences Announces First U.S. Procedure with the CellFX nsPFA Percutaneous Electrode System
BU
Pulse Biosciences Reports Business Updates and First Quarter 2024 Financial Results
BU
Pulse Biosciences Announces Timing of Rights Offering for Up to $60,000,000
BU
Pulse Biosciences Schedules First Quarter 2024 Financial Results Conference Call for May 7, 2024
BU
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
BU
Pulse Biosciences Announces Plans to Initiate a Rights Offering
BU
Pulse Biosciences Schedules Fourth Quarter & Full Year 2023 Financial Results Conference Call for March 28, 2024
BU
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
BU
PULSE BIOSCIENCES ANNOUNCES POSITIVE 60-DAY FOLLOW-UP EVALUATIONS FOR INITIAL PATIENTS TREATED IN THE CELLFX NSPFA 360-degree CARDIAC CATHETER FIRST-IN-HUMAN FEASIBILITY STUDY
AQ
Pulse Biosciences Announces Positive 60-Day Follow-Up Evaluations for Initial Patients treated in the CellFX® nsPFA™ 360° Cardiac Catheter First-in-Human Feasibility Study
BU
Pulse Biosciences Announces Preliminary Findings from its CellFX nsPFA 360 Cardiac Catheter First-In-Human Feasibility Study to be Featured in Podium Presentation at the AF Symposium
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. PLSE Stock
  4. News Pulse Biosciences, Inc.
  5. Press Releases